Press Release

Posted by Repositive, November 2020

Repositive expands global cancer model network with CRO from Finland

CAMBRIDGE, UK – (November 10, 2020) – Repositive, the world’s largest directory of preclinical cancer models, has expanded its global network of contract research organisation (CRO) partners with the addition of Pharmatest, a CRO providing clinically predictive preclinical efficacy services for oncology and skeletal diseases. Pharmatest brings to the partnership more than 20 years of experience in disease modelling, enabling Repositive to further grow its global reach to serve more biopharmaceutical companies in their quest for the right preclinical cancer models to accelerate oncology drug development programmes.

“At Repositive, we are committed to establishing new partnerships with specialist CROs to further enhance and strengthen our world-class offering of preclinical cancer models to biopharmaceutical researchers worldwide,” said Fiona Nielsen, CEO of Repositive. “Our collaboration with Pharmatest will enable us to do just that. By adding new models to the Repositive Cancer Models Platform, we will continue to support researchers in their preclinical work, providing them with a wider selection of models to choose from, thereby facilitating improved accuracy during the drug discovery process.”

At present, the Repositive Cancer Models Platform displays curated and standardised metadata from over 8,000 preclinical cancer models. Biopharmaceutical researchers can browse the available models with the option of filtering content by primary site, model type and subtype, gene mutation, variant, treatment, and treatment response. In vivo oncology researchers and in-house bioinformatics teams can rely on the platform for automated processing, organisation and streamlining of cancer model inventories, while the system’s easy-to-access interface allows complex modelling queries to be effortlessly performed.

“We chose to partner with Repositive because of their ground-breaking, compelling platform, which helps to connect key players in the preclinical cancer research field,” said Dr Jukka Rissanen, CEO of Pharmatest. “At Pharmatest, we have unique expertise in the field of bone metastases that we want to be able to share as widely as possible and collaborating with Repositive seems like a great way to do this.”

Repositive also offers the Cancer Models Scout, a specialist and confidential concierge service, which provides tailored model recommendations to researchers based on a search across Repositive’s extensive global network of more than 20,000 preclinical cancer models. This helps to accelerate the sourcing of models for preclinical oncology studies, with a proven track record of saving researchers months to years by connecting them to the right models in a much faster timeframe.

More information about the Repositive Cancer Models Platform is available here.


About Repositive

Repositive operates as a social enterprise, with the ultimate goal of helping to accelerate cancer drug development and bring treatments and cures to patients more quickly. They partner with contract research organisations (CROs) worldwide to organise and curate their cancer model data, and present this inventory of models online, via their Cancer Models Platform. Repositive’s main mission is to help preclinical oncology researchers speed up their projects and increasing translational success by enabling them to find and source the most suitable cancer models for their needs.

About Pharmatest

Pharmatest is a contract research organisation based in Finland, specialising in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases. In oncology, Pharmatest specialise in orthotopic and metastasis models, with particular expertise in bone metastasis models. Their capabilities include in vitro assays, in vivo models and ex vivo bone analysis services.


Repositive Marketing Contact

Henrietta Bull
Marketing Coordinator
henrietta@repositive.io